In the development of central nervous system (CNS) drugs, the blood–brain barrier (BBB)
restricts many drugs from entering the brain to exert therapeutic effects. Although many …

The treatment of central nervous system (CNS) disease has long been difficult due to the
ineffectiveness of drug delivery across the blood-brain barrier (BBB). This review …

The blood–brain barrier (BBB) denies many therapeutic agents access to brain tumours and
other diseases of the central nervous system (CNS). Despite remarkable advances in our …

Neuropharmaceutics is the largest potential growth sector of the pharmaceutical industry.
However, this growth is blocked by the problem of the blood–brain barrier (BBB). Essentially …

The blood-brain barrier (BBB) and blood-cerebrospinal fluid (BCSF) barriers are critical
determinants of CNS homeostasis. Additionally, the BBB and BCSF barriers are formidable …

While neurodegenerative diseases and cancers are on the rise, treatments for diseases of
the central nervous system (CNS) remain limited. The blood brain barrier (BBB) poses the …

The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central
nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial …

The blood–brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This
property arises from the epithelial-like tight junctions within the brain capillary endothelium …

The development of new drugs for the brain has not kept pace with progress in the
molecular neurosciences, because the majority of new drugs discovered do not cross the …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …